Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Zimmermann

Showing results (81-90 of 279) with videos related to

Pageof 28
Sort By:
Haematologica|November 30, 2023
Deciphering the molecular complexity of the IKZF1<sup>plus</sup> genomic profile using Optical Genome MappingJonathan L Lühmann, Martin Zimmermann, Winfried Hofmann, et al.
Glycobiology|May 10, 2011
Occurrence of the human tumor-specific antigen structure Galβ1-3GalNAcα- (Thomsen-Friedenreich) and related structures on gut bacteria: prevalence, immunochemical analysis and structural confirmationGemma Henderson, Philippe Ulsemer, Ute Schöber, et al.
British Journal of Haematology|August 4, 2017
Excellent outcome with limited treatment in paediatric patients with marginal zone lymphomaOlga Makarova, Ilske Oschlies, Stephanie Müller, et al.
Haematologica|January 26, 2013
NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemiaObul R Bandapalli, Martin Zimmermann, Corinne Kox, et al.
Journal of Oncology|August 31, 2019
Mutated <i>WT1</i>, <i>FLT3-ITD,</i> and <i>NUP98-NSD1</i> Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid LeukemiaNaghmeh Niktoreh, Christiane Walter, Martin Zimmermann, et al.
Leukemia|November 9, 2022
Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphomaRex K H Au-Yeung, Laura Arias Padilla, Martin Zimmermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2006
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98Ursula Creutzig, Martin Zimmermann, Thomas Lehrnbecher, et al.
Blood|March 30, 2007
Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphomaChristine Damm-Welk, Kerstin Busch, Birgit Burkhardt, et al.
Blood|December 4, 2013
Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphomaChristine Damm-Welk, Lara Mussolin, Martin Zimmermann, et al.
British Journal of Haematology|July 21, 2018
Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trialStephan Fuhrmann, Richard Schabath, Anja Möricke, et al.
Pageof 28

Showing results (81-90 of 279) with videos related to

Sort By:
Pageof 28
Haematologica|November 30, 2023
Deciphering the molecular complexity of the IKZF1<sup>plus</sup> genomic profile using Optical Genome MappingJonathan L Lühmann, Martin Zimmermann, Winfried Hofmann, et al.
Glycobiology|May 10, 2011
Occurrence of the human tumor-specific antigen structure Galβ1-3GalNAcα- (Thomsen-Friedenreich) and related structures on gut bacteria: prevalence, immunochemical analysis and structural confirmationGemma Henderson, Philippe Ulsemer, Ute Schöber, et al.
British Journal of Haematology|August 4, 2017
Excellent outcome with limited treatment in paediatric patients with marginal zone lymphomaOlga Makarova, Ilske Oschlies, Stephanie Müller, et al.
Haematologica|January 26, 2013
NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemiaObul R Bandapalli, Martin Zimmermann, Corinne Kox, et al.
Journal of Oncology|August 31, 2019
Mutated <i>WT1</i>, <i>FLT3-ITD,</i> and <i>NUP98-NSD1</i> Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid LeukemiaNaghmeh Niktoreh, Christiane Walter, Martin Zimmermann, et al.
Leukemia|November 9, 2022
Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphomaRex K H Au-Yeung, Laura Arias Padilla, Martin Zimmermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2006
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98Ursula Creutzig, Martin Zimmermann, Thomas Lehrnbecher, et al.
Blood|March 30, 2007
Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphomaChristine Damm-Welk, Kerstin Busch, Birgit Burkhardt, et al.
Blood|December 4, 2013
Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphomaChristine Damm-Welk, Lara Mussolin, Martin Zimmermann, et al.
British Journal of Haematology|July 21, 2018
Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trialStephan Fuhrmann, Richard Schabath, Anja Möricke, et al.
Pageof 28